NASDAQ:ZYNE - Zynerba Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.56
  • Forecasted Upside: 134.20 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.13 (-2.80%)

This chart shows the closing price for ZYNE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zynerba Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYNE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYNE

Analyst Price Target is $10.56
▲ +134.20% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Zynerba Pharmaceuticals in the last 3 months. The average price target is $10.56, with a high forecast of $18.00 and a low forecast of $7.25. The average price target represents a 134.20% upside from the last price of $4.51.

This chart shows the closing price for ZYNE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Zynerba Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021Cantor FitzgeraldBoost Price TargetOverweight$6.00 ➝ $8.00High
3/10/2021Roth CapitalLower Price TargetBuy$8.00 ➝ $7.25High
2/5/2021Canaccord GenuityReiterated RatingBuy$18.00High
1/20/2021Canaccord GenuityReiterated RatingBuyMedium
12/21/2020HC WainwrightLower Price TargetBuy$12.00 ➝ $9.00Low
9/14/2020Needham & Company LLCReiterated RatingHoldMedium
8/10/2020Needham & Company LLCReiterated RatingHoldMedium
7/1/2020HC WainwrightReiterated RatingBuy$12.00Medium
7/1/2020Canaccord GenuityLower Price TargetBuy$18.00 ➝ $12.00High
7/1/2020Needham & Company LLCDowngradeBuy ➝ HoldMedium
7/1/2020Cantor FitzgeraldLower Price TargetOverweight$24.00 ➝ $8.00Medium
6/29/2020LADENBURG THALM/SH SHReiterated RatingBuy$26.00Medium
5/28/2020Cantor FitzgeraldBoost Price TargetOverweight$21.00 ➝ $24.00High
5/22/2020Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $21.00High
4/16/2020Needham & Company LLCReiterated RatingBuy$16.00High
2/20/2020HC WainwrightReiterated RatingBuyLow
12/31/2019Roth CapitalInitiated CoverageBuy$12.00High
10/21/2019Needham & Company LLCInitiated CoverageBuy$18.00High
9/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00High
9/16/2019Jefferies Financial GroupReiterated RatingHold$11.00Low
6/28/2019Canaccord GenuitySet Price TargetBuy$18.00High
5/31/2019Cantor FitzgeraldBoost Price TargetOverweight$12.00 ➝ $22.00Medium
5/30/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00Medium
5/6/2019LADENBURG THALM/SH SHReiterated RatingBuy$26.00Low
4/30/2019Roth CapitalInitiated CoverageBuy$36.00High
4/22/2019Canaccord GenuityInitiated CoverageBuy ➝ Buy$8.09High
3/18/2019HC WainwrightReiterated RatingBuyHigh
3/7/2019Cantor FitzgeraldReiterated RatingBuy$11.00Medium
12/17/2018Cantor FitzgeraldSet Price TargetBuy$21.00High
12/5/2018Cantor FitzgeraldSet Price TargetBuy$21.00Medium
11/13/2018HC WainwrightSet Price TargetBuy$23.00High
10/2/2018Cantor FitzgeraldReiterated RatingBuy$21.00Medium
9/21/2018Cantor FitzgeraldInitiated CoverageOverweight$21.00Medium
8/6/2018HC WainwrightSet Price TargetBuy$23.00High
8/3/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$18.00 ➝ $15.00High
8/2/2018Cantor FitzgeraldSet Price TargetBuy$20.00High
7/13/2018HC WainwrightSet Price TargetBuy$23.00High
7/13/2018Canaccord GenuitySet Price TargetBuy$18.00High
7/5/2018Canaccord GenuityReiterated RatingBuy$18.00High
7/5/2018HC WainwrightReiterated RatingBuy$23.00High
7/5/2018Cantor FitzgeraldSet Price TargetBuy$20.00High
5/9/2018Cantor FitzgeraldSet Price TargetBuy$20.00Medium
5/8/2018OppenheimerReiterated RatingHoldLow
4/25/2018Cantor FitzgeraldSet Price TargetBuy$20.00Low
4/16/2018HC WainwrightSet Price TargetBuy$23.00Medium
3/13/2018Seaport Global SecuritiesReiterated RatingBuyLow
3/13/2018OppenheimerReiterated RatingHoldMedium
3/13/2018HC WainwrightSet Price TargetBuy$23.00Medium
3/12/2018Cantor FitzgeraldSet Price TargetBuy$20.00Medium
3/6/2018HC WainwrightSet Price TargetBuy$23.00High
3/5/2018Cantor FitzgeraldInitiated CoverageBuy$17.00High
2/1/2018HC WainwrightReiterated RatingBuy ➝ Buy$23.00Medium
1/29/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$25.50High
1/26/2018Seaport Global SecuritiesInitiated CoverageBuy ➝ Buy$16.00High
1/3/2018Cantor FitzgeraldSet Price TargetBuy$17.00High
1/3/2018OppenheimerReiterated RatingHoldHigh
12/4/2017Cantor FitzgeraldSet Price TargetBuy$17.00High
12/4/2017Canaccord GenuitySet Price TargetOutperform ➝ Buy$15.00 ➝ $18.00High
11/20/2017Cantor FitzgeraldSet Price TargetBuy$17.00N/A
11/14/2017OppenheimerReiterated RatingHoldN/A
11/14/2017Piper Jaffray CompaniesBoost Price Target$16.00 ➝ $20.00N/A
10/2/2017Cantor FitzgeraldUpgradeNeutral ➝ Overweight$4.00 ➝ $17.00Low
10/1/2017Roth CapitalSet Price TargetBuy$15.00Medium
9/29/2017OppenheimerReiterated RatingHoldHigh
9/29/2017Canaccord GenuityBoost Price TargetBuy$9.00 ➝ $15.00High
9/28/2017Cantor FitzgeraldReiterated RatingHold$4.00High
9/28/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$7.00 ➝ $16.00High
8/18/2017Canaccord GenuitySet Price TargetBuy$35.00 ➝ $9.00Low
8/15/2017CIBCReiterated RatingOutperform ➝ Market PerformLow
8/15/2017Roth CapitalUpgradeNeutral ➝ Buy$15.00Low
8/15/2017HC WainwrightSet Price TargetHold$7.00Low
8/15/2017Jefferies Financial GroupDowngradeBuy ➝ Hold$12.00 ➝ $7.00Low
8/14/2017OppenheimerDowngradeOutperform ➝ Market PerformLow
8/14/2017Cantor FitzgeraldSet Price TargetHold$4.00High
8/14/2017Maxim GroupReiterated RatingHoldHigh
8/9/2017Jefferies Financial GroupReiterated RatingBuy$32.00 ➝ $12.00Medium
8/8/2017Cantor FitzgeraldReiterated RatingOverweight$28.00High
8/8/2017Roth CapitalDowngradeBuy ➝ Neutral$30.00 ➝ $7.00Medium
8/8/2017HC WainwrightDowngradeBuy ➝ Neutral$30.00 ➝ $7.00High
8/7/2017OppenheimerSet Price TargetBuy$8.00High
8/7/2017Maxim GroupDowngradeBuy ➝ HoldHigh
8/7/2017Cantor FitzgeraldDowngradeOverweight ➝ Neutral$28.00 ➝ $4.00High
8/7/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$42.00 ➝ $7.00High
8/1/2017Cantor FitzgeraldSet Price TargetBuy$28.00High
8/1/2017Maxim GroupSet Price TargetBuy$32.00High
8/1/2017HC WainwrightSet Price TargetBuy$30.00High
7/9/2017Jefferies Financial GroupReiterated RatingBuy$32.00Medium
6/26/2017Maxim GroupSet Price TargetBuy$32.00N/A
6/10/2017Roth CapitalSet Price TargetBuy$30.00High
6/8/2017Cantor FitzgeraldSet Price TargetBuy$28.00Low
6/8/2017Maxim GroupReiterated RatingBuy$32.00Low
5/25/2017Jefferies Financial GroupReiterated RatingBuy$32.00High
5/13/2017Canaccord GenuitySet Price TargetBuy$35.00Low
5/13/2017Roth CapitalSet Price TargetBuy$30.00Low
5/9/2017Cantor FitzgeraldReiterated RatingBuy$28.00High
4/1/2017OppenheimerSet Price TargetBuy$29.00Low
3/28/2017HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $30.00High
3/27/2017Cantor FitzgeraldSet Price TargetBuy$28.00High
3/20/2017Roth CapitalBoost Price TargetBuy$25.00 ➝ $30.00Low
3/13/2017Roth CapitalSet Price TargetBuy$25.00Low
3/13/2017Maxim GroupReiterated RatingBuy$32.00Medium
2/23/2017Maxim GroupInitiated CoverageBuy ➝ Buy$32.00N/A
1/5/2017Cantor FitzgeraldReiterated RatingOverweight$28.00N/A
12/21/2016Cantor FitzgeraldInitiated CoverageOverweight$28.00N/A
12/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$42.00N/A
12/18/2016OppenheimerSet Price TargetBuy$29.00N/A
12/16/2016HC WainwrightReiterated RatingBuy$22.00N/A
12/6/2016Jefferies Financial GroupReiterated RatingBuy ➝ Buy$32.00N/A
11/15/2016HC WainwrightReiterated RatingBuyN/A
10/7/2016HC WainwrightInitiated CoverageBuy$22.00N/A
9/7/2016Canaccord GenuityReiterated RatingBuy$35.00N/A
9/6/2016Roth CapitalSet Price TargetBuy$25.00N/A
8/16/2016Canaccord GenuityReiterated RatingBuy$35.00N/A
8/16/2016Canaccord GenuitySet Price TargetBuy$35.00N/A
8/12/2016Piper Jaffray CompaniesReiterated RatingOverweight$42.00N/A
7/26/2016Piper Jaffray CompaniesReiterated RatingOverweight$42.00N/A
(Data available from 7/23/2016 forward)
Zynerba Pharmaceuticals logo
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Read More

Today's Range

Now: $4.51
Low: $4.50
High: $4.65

50 Day Range

MA: $5.18
Low: $4.49
High: $5.98

52 Week Range

Now: $4.51
Low: $3.15
High: $9.00


471,024 shs

Average Volume

3,176,493 shs

Market Capitalization

$186.05 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Zynerba Pharmaceuticals?

The following sell-side analysts have issued reports on Zynerba Pharmaceuticals in the last year: Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for ZYNE.

What is the current price target for Zynerba Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Zynerba Pharmaceuticals in the last year. Their average twelve-month price target is $10.56, suggesting a possible upside of 134.2%. Canaccord Genuity has the highest price target set, predicting ZYNE will reach $18.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $7.25 for Zynerba Pharmaceuticals in the next year.
View the latest price targets for ZYNE.

What is the current consensus analyst rating for Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYNE will outperform the market and that investors should add to their positions of Zynerba Pharmaceuticals.
View the latest ratings for ZYNE.

What other companies compete with Zynerba Pharmaceuticals?

How do I contact Zynerba Pharmaceuticals' investor relations team?

Zynerba Pharmaceuticals' physical mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company's listed phone number is 484-581-7505 and its investor relations email address is [email protected] The official website for Zynerba Pharmaceuticals is